Company intelligence / Profile preview

KabiGen

Stockholm, Sweden

Ownership: Private
Development stage: Other

Overview

KabiGen was a pioneering Swedish biotechnology company established in 1983 as a subsidiary of KabiVitrum to specialize in recombinant DNA technology. The company was instrumental in the development and scale-up of biosynthetic human growth hormone, marketed as Genotropin, and recombinant blood coagulation factors. As a critical link between academic molecular biology research and industrial pharmaceutical production, KabiGen helped establish Sweden as a hub for modern biotechnology. Following the merger of its parent company with Pharmacia in 1990, KabiGen was integrated into Kabi Pharmacia, and its legacy continues through products now managed by Pfizer.

Therapeutic areas: HematologyEndocrinology
Modalities: Recombinant proteinHormone
Industry: Biotech

Partnerships

Genentech

Beyond the preview

Go deeper on KabiGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KabiGen.

Explore the full profile